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Among the strategies to optimize engraftment of cord blood (CB) stem cell transplantation (SCT), single CB
with the coinfusion of CD34þ stem cells from an HLA-mismatched auxiliary donor (haplo-cord) provides a
valid alternative for adult patients without a suitable donor. A total of 132 high-risk adult patients with
hematological malignancies from 3 Spanish institutions underwent myeloablative haplo-cord SCT. The me-
dian age was 37 years and median weight was 70 kg; 37% had active disease. The median number of post-
processing CB total nucleated and CD34þ cells was 2.4  107/kg (interquartile range [IQR], 1.8 to 2.9) and
1.4  105/kg (IQR, .9 to 2), respectively. Neutrophil engraftment occurred in a median of 11.5 days (IQR, 10.5 to
16.5) and platelet engraftment at 36 days (IQR, 25.5 to 77). Graft failure was 2% overall and only 9% for CB.
Cumulative incidence of acute graft-versus-host disease (GHVD) grades II to IV was 21% and cumulative
incidence of chronic GVHD was 21%. Median follow-up was 60 months (range, 3.5 to 163). Overall survival
was 43.5%, event-free survival was 38.3%, nonrelapse mortality was 35%, and relapse was 20% at 5 years.
Myeloablative haplo-cord SCT results in fast engraftment of neutrophils and platelets, low incidences of acute
and chronic GVHD, and favorable long-term outcomes using single CB units with relatively low cell content.
Moreover, CB cell dose had no impact on CB engraftment and survival in this study. Therefore, haplo-cord SCT
expands donor availability while reducing CB cell dose requirements.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Unrelated cord blood (CB) is now considered 1 of the
front-line stem cells sources for high-risk patients in need for
allogeneic stem cell transplantation (SCT) without immedi-
ate access to a suitable adult donor [1,2] The major disad-
vantage of single-unit CB SCT is the late hematopoietic
recovery, which leads to increased early morbidity and
mortality after transplantation [3]. From the broaddgments on page 2021.
uests: Mi Kwon, MD, Gregorio Marañon
rtment of Hematology, Hospital General
adrid, Spain.
.madrid.org (M. Kwon).
14.08.024
ty for Blood and Marrow Transplantation.experience with single CB SCT in adults, a number of factors
have been associated with graft failure and delayed
engraftment, including low total nucleated cell (TNC) and
CD34þ cell dose [4], quality of cryopreserved hemopoietic
stem cells [5], limited number of accessory cells for
engraftment (lymphocytes subsets or mesenchymal cells)
[6], degree of HLA incompatibility, CB stem cells homing
capacity, and presence of donor-speciﬁc antibodies [7,8].
It iswell established that unit cell quantity is amajor factor
for hematopoietic recovery and nonrelapse mortality (NRM)
[9,10]. In the adult setting, current cell dose requirement
criteria for unit selection depends on HLA matching. The
minimum acceptable content of precryopreservation TNC is
2.5107/kg (kilogramof patient bodyweight), and for CD34þ,
1.5  105/kg for closely matched CB units (eg, 5/6 or 6/6
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high-resolution matching at HLA-DRB1, with higher TNC tar-
gets in the setting of greater mismatch [4,9,10]. Moreover, for
nonmalignant disorders, cell dose requirements are even
higher. Thus,manyadult patients lack suitable units according
to the current cell dose criteria, especially in certain pop-
ulations [11]. To overcome the limitation of graft cell dose,
several efforts have been undertaken in recent years,
including infusion of 2 umbilical CB units [12], ex vivo
expansion of cells [13], and intrabone infusion [14].
In this context, infusion of a single CB unit together with a
limited number of mobilized CD34þeselected peripheral
blood (PB) stem cells from an HLA-mismatched third-party
donor (TPD), named dual or haplo-cord transplantation, has
been developed. Haplo-cord SCT has been shown to reduce
the post-transplantation period of neutropenia and related
early morbidity and mortality associated with single CB
transplantation, mostly using units with relatively low cell
content [15-19]. Furthermore, CB cell dose had no measur-
able impact on outcomes [18]. Here we report the results of
the largest cohort of adult patients who underwent trans-
plantation with the haplo-cord procedure, emphasizing the
hemopoietic recovery and graft features.
PATIENTS AND METHODS
Eligibility
The study included 132 adult patients from 3 Spanish transplantation
centers (89 from Hospital Universitario Puerta de Hierro, 28 from Hospital
Universitario Gregorio Marañón, and 15 from Hospital Duran i Reynals) who
had high-risk hematological malignancies and severe bone marrow (BM)
failure syndromes and who were undergoing myeloablative haplo-cord
transplantation from 1999 to 2012, with a minimum follow-up of
6 months after transplantation. The study was approved by all the local
institutional review boards and all donors and recipients gave written
informed consent.
Graft Selection and Processing
For CB units, a match of at least 4 out of 6 HLA loci considering low
resolution for HLA-A and HLA-B and high resolution for HLA-DRB1 was
preferable. CB units were selected on the basis of TNC, CD34þ, and HLA
matching as determined before freezing, focusing on cell dose at the
expense ofmatching. CB units with the higher content of cryopreserved cells
after volume reduction were preferable, with a minimum of 1.2  107 TNC/
kg and 1  105 CD34þ cells/kg. ABO compatibility was used as secondary
selection criteria.
Donors for the HLA-mismatched CD34þ cells were sought among pa-
tients’ ﬁrst-degree relatives. Given the initial reported cases of graft failure
related to the use of maternal donors [15,16], nonmaternal relatives were
preferred. If no relatives were available, an unrelated individual was selected
as donor. Granulocyte colonyestimulating factor (10 mg/kg/day) was
administrated for 4 consecutive days to all donors and cells were collected
with a continuous ﬂow apheresis device. Selection of CD34þ cells was per-
formed by positive immunomagnetic procedures to obtain a ﬁnal product
with around 2.5 to 3  106 CD34þ cells/kg and less than 1 104 CD3þ cells/
kg of recipient body weight, as previously described [15-17].
Conditioning Regimen and Graft-versus-host Disease Prophylaxis
The conditioning regimen has been previously described [17,19]. Brieﬂy,
patients received ﬂudarabine 30 mg/m2 (days -8 to -5), cyclophosphamide
60 mg/kg (days -4 and -3), and i.v. busulfan 3.2 mg/kg (days -6 and -5) (oral
busulfan 4 mg/kg until 2006) or 10 Gy of fractionated total body irradiation
(TBI). Up to the year 2000, equine antithymocyte globulin (Linfoglobulin,
Lyon, France; Imtix, Lyon, France; Sangstat, Lyon, France) was given at
30 mg/kg on day -1 and thereafter rabbit antithymocyte globulin (Tim-
oglobulin, Marcy L’etoile, France; Genzyme, Marcy L’etoile, France) 2 mg/kg
on days -2 and -1. CB cells were infused on day 0 followed by the TPD cells
either the same day or on day þ1. As graft-versus-host disease (GVHD)
prophylaxis, patients received cyclosporine A from day -5, ﬁrst intrave-
nously and then orally, and methylprednisolone 1 to 2 mg/kg from day -2,
tapered until suspension on day þ14. In the absence of GVHD manifesta-
tions, cyclosporine Awas tapered when full CB engraftment was achieved or
from day þ50. Infectious prophylaxis and supportive care were previously
described [16,17,19].Endpoint Deﬁnitions and Assessments
Engraftment, NRM, disease relapse or progression, event-free survival
(EFS), and overall survival (OS) were deﬁned as primary endpoints. Myeloid
engraftment was deﬁned as an absolute neutrophil count of .5  109/L or
greater for 3 consecutive days. Platelet engraftment was deﬁned as a
platelet count of 20  109/L or higher, without transfusion support for 7
consecutive days. Patients who survived more than 30 days after trans-
plantation and who failed to achieve myeloid engraftment were considered
graft failures.
Chimerism was determined by quantitative analysis of informative
microsatellite DNA polymorphisms as previously described in BM and/or PB
[20]. BM samples were analyzed on days þ30, þ100, þ180, þ365 and once a
year thereafter. PB samples were obtained weekly from day þ14 in patients
with mixed chimerism, once a month during the ﬁrst year of trans-
plantation, and every other month thereafter. Graft rejectionwas deﬁned as
graft failure with documentation of return of recipient hematopoiesis as
determined by chimerism studies. CB graft failurewas deﬁned as absence of
CB-speciﬁc alleles at dayþ30 (cutoff <1% for whole BM and PB samples and
<5% for leukocyte lineages).
NRM was deﬁned as death from any cause without previous disease
relapse or progression. EFS was deﬁned as the time from transplantation to
disease relapse or progression, retransplantation because of CB graft failure,
or death from any cause, whichever occurred ﬁrst. OS was deﬁned as the
time from transplantation to death from any cause, and surviving patients
were censored at last follow-up. Response to therapy before and after
transplantation followed the National Cancer Institute criteria, revised by
the International Working Group in acute myeloid leukemia. Acute GVHD
(aGVHD) and chronic GVHD (cGVHD) were scored according to the estab-
lished criteria.
Follow-up of patients was updated in October 2012.Statistical Analysis
Quantitative variables were expressed as median and either range or
interquartile range (IQR, 25th and 75th percentiles). Qualitative variables
were expressed as frequency and percentage. Fisher exact test or chi-
square were used to test for the association between qualitative vari-
ables. Estimates of EFS and OS were calculated using the Kaplan-Meier
method, including 95% conﬁdence interval (95% CI). A Cox proportional
hazards model was used for multivariable analysis. Cumulative incidence
curves and competing-risk regression were performed as alternatives to
Cox regression for survival data in presence of competing risks [21]. In
our case, competitor events were death and any other occurrence that
prevents the appearance of the event under study. This model estimates
the hazard ratio known as subdistribution hazard or subhazard ratio
(sHR).
For the cumulative incidence estimate of neutrophil recovery, death
before day þ30 was considered a competing event. For the cumulative
incidence of platelet engraftment and full CB chimerism, death and
retransplantation were considered competing events. NRM and relapse
were considered competing events for each other, in addition to retrans-
plantation for both of them. Hazard ratios and sHR models were adjusted
initially for age, sex, weight, patient cytomegalovirus (CMV) serostatus, CB-
patient ABO compatibility, diagnosis, pre-SCTmorphologic disease, previous
SCT, TBI-based conditioning regimen, CB TNC/kg, CB CD34þ/kg, CB-patient
HLA disparities, TPD-patient HLA disparities, and the use of mothers as
TPD. Finally, only variables with P < .20 were kept in the model.
Except for the cumulative incidence, all calculations were made with
SPSS (IBM SPSS Statistics for Windows, Version 21.0. Armonk, NY: IBM
Corp.).RESULTS
Patients
Characteristics of the patients included in this study are
shown in Table 1. One hundred and thirty-two consecutive
adult patients underwent haplo-cord SCT between 1999 and
2012. Brieﬂy, the cohort comprised 80 (61%) males and 52
(39%) females with a median age of 37 years (IQR, 28 to 48).
Median weight was 70 kg (range, 42 to 111), with 10% of the
patients > 90 kg of weight. One hundred patients (75%) had
acute leukemia (acute myeloid leukemia, 44%, and acute
lymphoblastic leukemia, 31%), 49 (49%) patients underwent
transplantation in ﬁrst complete remission. Forty-nine 49
(37%) patients had active disease at the time of trans-
plantation. In all, 16 (12%) patients had relapsed after a
Table 1
Characteristics of Patients, Grafts, and Transplantation Procedures (N ¼ 132)
Characteristic Value
Patients
Age, median (IQR), yr 37 (28-48)
Sex
Male 80 (61)
Female 52 (39)
Weight, median (range), kg 70 (42-111)
Diagnosis and disease status at transplantation
AML 57 (43)
CR1 28 (49)
Active disease 20 (35)
ALL 42 (32)
CR1 21 (50)
Active disease 8 (19)
MDS 12 (10)
Lymphoproliferative disease 12 (9)
CML 6 (5)
Other* 3 (2)
Active disease 49 (37)
Previous transplantation 24 (18)
Autologous/allogeneic 16 (12)/8 (6)
CMV seropositivity before transplantation 104 (79)
Grafts and transplantations
ABO blood group mismatch
Major 28 (23)
Minor 34 (28)
None 60 (49)
Conditioning
TBI-containing regimen 56 (43)
BU-FDR-CTX 70 (54)
Othery 4 (3)
ATG 132 (100)
GVHD prophylaxis
CsA þ steroids 132 (100)
CB cells, median (IQR)z
TNC  107/kg 2.4 (1.8-2.9)
CD34þ  105/kg 1.4 (.9-2)
CB HLA match, graft-versus-host
6/6 15 (12)
5/6 46 (37)
4/6 57 (46)
3/6 7 (5)
CB HLA match, host-versus-graft
6/6 16 (13)
5/6 48 (38)
4/6 54 (43)
3/6 7 (5)
TPD cells, median (IQR)x
CD34þ  106/kg 2.5 (2.2-3)
CD3þ  104/kg .3 (.15-.45)
TPD HLA match
Haploidentical 92 (71)
Full mismatch 38 (29)
TPD
Related 110 (83)
Nonrelated 22 (17)
AML indicates acute myeloid leukemia; CR1, ﬁrst complete remission; ALL,
acute lymphoblastic leukemia; MDS, myelodysplastic syndrome; CML,
chronic myeloid leukemia; GVHD, graft-versus-host disease; TBI, total body
irradiation; BU, busulfan; FDR, ﬂudarabine; CTX, cyclophosphamide; ATG,
antithymocyte globulin, CsA, cyclosporine A; CB, cord blood; TNC, total
nucleated cells; TPD, third party donor.
Data presented are n (%) unless otherwise speciﬁed. IQR indicates the 25th
to 75th percentile.
* Two aplastic anemia and 1 myeloﬁbrosis.
y Two cases received TBI 200 rads, 2 cases received FDR-Citarabine-CTX-
ATG.
z After processing, before cryopreservation.
x Infused cells.
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enty (54%) transplantations were performed with the
busulfan-based preparative regimen and 56 (43%) patients
received TBI-based conditioning.The median follow-up for surviving patients was
60 months (range, 6 to 163).
Graft Features
Table 1 shows the characteristics of the grafts and trans-
plantations performed. Fifteen (12%) transplantations were
performed with a fully HLAematched (6/6) CB unit, 46 (37%)
received a 5/6-matched unit, and 57 (46%) received a 4/6-
matched unit.
The median number of postprocessing CB TNC and CD34þ
cells was 2.4107/kg (IQR,1.8 to 2.9) and 1.4105/kg (IQR, .9
to 2), respectively. Median number of TNC and CD34þ cells
for units with a 6/6 and 5/6 match was 2.3  107/kg (IQR, 1.7
to 2.7) and 1.2105/kg (IQR, .8 to 1.9), whereas for units with
a 4/6 match, median TNC and CD34þ cells was 2.4  107/kg
(IQR,1.8 to 3) and 1.5105/kg (IQR, .9 to 2), respectively, with
no signiﬁcant differences. Twenty-eight (23%) trans-
plantations were performed with CB units with a major ABO
blood group mismatch and 34 (28%) were performed with a
minor mismatch.
The HLA-mismatched TPD was a relative in 110 (83%)
cases, 5 of them a mother, and an unrelated individual in 22
(17%) cases. In all, 92 (71%) were haploidentical donors and
38 (29%) were fully mismatched donors. The median number
of the infused TPD CD34þ cells was 2.5  106/kg (IQR, 2.3 to
3), with a median number of CD3þ cells of .3  104/kg (IQR,
.15 to .45).
Engraftment and Chimerism
The cumulative incidence of myeloid engraftment was
95% at 40 days (95% CI, 89% to 98%) (Figure 1) in a median
time of 11.5 days (IQR, 10.5 to 16.5). In the multivariate
analysis, the presence of active disease at transplantation
was associatedwith lower rate and slower engraftment (sHR,
.564; 95% CI, .377 to .843; P ¼ .005), whereas TBI-based
conditioning (sHR, 1.617; 95% CI, 1.149 to 2.275; P ¼ .006)
and CB unit TNC content (sHR, 1.285; 95% CI, 1.076 to 1.534;
P ¼ .005) were both favorable factors. However, no TNC cut-
off value could be identiﬁed. Furthermore, CB unit TNC
content did not inﬂuence myeloid engraftment in the ma-
jority of cases (n ¼ 96) and in those showing engraftment
before day 16 (sHR, .9; 95% CI, .74 to 1.15; P¼ .50) (Figure 1B).
Nevertheless, TNC correlated with myeloid engraftment dy-
namics in the minority of patients who showed engraftment
beyond day 16 (n ¼ 28) (sHR, 1.83; 95% CI, 1.02 to 3.27; P ¼
.004) (Figure 1C). No signiﬁcant differences were found
between patients showing engraftment before and beyond
day 16 in terms of diagnosis, demographics, CB unit, and TPD
characteristics. However, in 42% of those patients showing
myeloid engraftment beyond day 16, TPD were scarcely seen
in early post-transplantation chimerism studies.
The cumulative incidence of platelet recovery was 78% at
100 days (95% CI, 71% to 85%) (Figure 1D) with a median time
of engraftment of 36 days (IQR, 25.5 to 77). In the multivar-
iate analysis, factors negatively inﬂuencing platelet engraft-
ment were the presence of active disease (sHR, .377; 95% CI,
.238 to .598; P < .001) and the use of mothers as TPD (sHR,
.268; 95% CI, .093 to .772; P ¼ .01).
Failure of both CB and TPD donor grafts was seen in 3
cases (2%). Post-thawing growth of colony-forming units was
poor in 1 of the cases and speciﬁc HLA antibodies were
detected in another case. Eight patients showed engraftment
of TPD cells only. Of them, 5 cases showed poor post-thawing
colony-forming units. Of note, these patients maintained
acceptable blood counts until a salvage transplantation could
Figure 1. (A) Cumulative incidence of neutrophil engraftment. (B) Correlation between CB content of TNC ( 107/kg) and time to neutrophil engraftment. (C) Myeloid
engraftment dynamics in 28 patients with engraftment beyond day þ16 according to cord blood TNC content. (D) Platelet engraftment.
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and all of them engrafted, and 1 received a haploidentical
transplant with early relapse. Finally, 2 patients developed
rejection of the CB graft. Overall, CB graft failure was docu-
mented in 13 cases (9%).
The majority of patients showed PB mixed chimerism on
days þ14 and þ21, with variable percentages of CB and TPD
cells, superseded by stable CB engraftment. Cumulative
incidence of peripheral blood full CB chimerism was 80% at
180 days (95% CI, 70% to 86%) (Figure 2) achieved in a median
time of 61 days (IQR, 29.5 to 135). All patients who achieved
full CB chimerism showed full sustained CB engraftment in
the last follow-up or until relapse. In the multivariate anal-
ysis, factors adversely inﬂuencing achievement of full CB
chimerism were recipient weight (sHR, .978; 95% CI, .965 to
.992; P ¼ .002) and previous transplantation (sHR, 1.725; 95%
CI, 1.038 to 2.866; P ¼ .035). Cumulative incidence of full CB
chimerism showed no signiﬁcant differences between pa-
tients who underwent transplantation with units containing
< 2.5 or > 2.5  107/kg of TNC, and < 1.5 or > 1.5  105/kg ofFigure 2. (A) Cumulative incidence of full CB chimerism in peripheral blood. (B)
content  2.5  107/kg and < 2.5  107/kg and (C) according to cord blood HLA-matCD34þ cells (Figure 2, Supplementary Figure 1). Similarly, the
cumulative incidence of full CB chimerism was not different
between transplantations performed with 4/6 match
compared with those performed with units 5/6 and 6/6
matched (P ¼ .326) (Figure 2).GVHD
The cumulative incidence of grades II to IV aGVHD at
day þ100 was 21% (95% CI, 15% to 28%) (Figure 3). Of note,
only 9 patients from the whole series showed grades III to IV
aGVHD. In the multivariate analysis, the only factor associ-
ated with development of aGVHD was previous trans-
plantation (sHR, 2.911; 95% CI, 1.249 to 6.783; P ¼ .013). The
cumulative incidence of overall chronic GVHD and extensive
cGVHD was 21% (95% CI, 13% to 31%) (Figure 3) and 5% (95%
CI, 3% to 8%), respectively. In the multivariate analysis,
recipient age (sHS, .960, 95% CI, .927 to .995; P ¼ .027) and
minor ABO incompatibility (sHR, 7.906; 95% CI, 1.668 to
37.471; P ¼ .009) inﬂuenced the occurrence of cGVHD.Cumulative incidence of full CB chimerism in cases with cord blood TNC
ch: 4/6 versus 5/6 to 6/6.
Figure 3. Cumulative incidence of (A) acute GVHD grades II to IV and (B) chronic GVHD.
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With amedian follow-up of 60months (range, 3.5 to 163),
the estimated 5-year OS and EFS were 43.5% (95% CI, 34.5% to
53%) and 38.3% (95% CI, 29.5% to 47%), respectively (Figure 4).
The only factors associated with lower EFS were active dis-
ease at the time of transplantation (sHR, 2.56; 95% CI, 1.40 to
4.68; P ¼ .002) and diagnosis of lymphoproliferative disease
(sHR, 2.6; 95% CI, 1.31 to 5.04; P ¼ .006). EFS was 51.5% for
patients in complete remission and 21% for those with active
disease (Figure 4). Cumulative incidence of relapse was 20%
at 2 and 5 years (95% CI, 14% to 28%) (Figure 5). In the
multivariate analysis, no independent factors could be
identiﬁed; however, use of TBI in the conditioning regimen
(sHR, .415; 95% CI, .165 to 1.043; P ¼ .06) and presence of
active disease (sHR, 2.219; 95% CI, .878 to 5.604; P ¼ .09)
showed an association with lower and higher rates of
relapse, respectively.
EFS and relapse were not inﬂuenced by the speed of CB
engraftment, with a similar EFS and cumulative incidence of
relapse for those patients achieving full CB chimerism before
and after day þ62 (percentile 65). Similar EFS and cumula-
tive incidence of relapse were also found in those achieving
full CB chimerism before and after day þ42 (percentile 45).
NRM
The 44 transplantation-related deaths occurred at a me-
dian of 2.5 months after transplantation (IQR, 1.2 toFigure 4. (A) Event-free survival and overall survival. (B) Event-free survival in patie6.2 months). Cumulative incidence of NRM at 100 days,
1 year, and 5 years was 21% (95% CI, 15% to 28%), 33% (95% CI,
25% to 41%), and 35% (95% CI, 27% to 43%), respectively
(Figure 5). Unfavorable factors in the multivariate analysis
were older recipient age (sHR, 1.052; 95% CI, 1.013 to 1.093;
P ¼ .008), active disease (sHR, 2.242; 95% CI, 1.140 to 4.407;
P ¼ .019), and TBI-based conditioning (sHR, 4.006; 95% CI,
1.846 to 8.692; P ¼ .007).
Causes of Death
The causes of death were infection in 17 patients, at a
median time of 2.3 months (IQR, 1 to 4.5), with the following
etiologic agents: 6 CMV disease, 4 fungi, 3 bacteria, 1
adenovirus, 1 respiratory syncytial virus, 1 toxoplasmosis,
and 1 tripanosomiasis. Eight patients from the whole cohort
died from aGVHD (n ¼ 3) or cGVHD (n ¼ 5). Toxicity was
the cause of death in 19 patients: 6 pulmonary toxicity, 4
multiorgan failure, 3 hepatic veno-occlusive disease, 3
hemorrhagic complication, 2 graft failure, 1 Epstein-Barr
viruserelated post-transplantation lymphoproliferative dis-
order. Finally, relapse was the cause of death in 18 patients.
DISCUSSION
This study includes the largest number of adult patients
who underwent transplantation using single CB SCT sup-
ported by stem cells from a mismatched TPD and conﬁrms
that the haplo-cord approach is a real alternative for patientsnts who underwent transplantation in complete remission and active disease.
0
,2
,4
,6
,8
1
C
um
ul
at
iv
e 
In
ci
de
nc
e
Time after transplantation (months)
A
C
um
ul
at
iv
e 
In
ci
de
nc
e
Time after transplantation (months)
B
Figure 5. Cumulative incidence of (A) relapse and (B) NRM.
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achieves high rates of engraftment and provides the earliest
neutrophil recovery compared with other CB SCT strategies
because of early and transient engraftment of the third-party
graft (“bridge engraftment”) followed by long-term
engraftment of CB cells.
From the experience of single CB SCT, low cell content in
the transplanted product and a higher degree of HLA in-
compatibility have been identiﬁed as the main factors for
graft failure and late engraftment [4,22], limiting wider use
of CB SCT, especially in adults. Our experience with haplo-
cord SCT in adult patients shows high rates of early
engraftment accomplished with single units of relatively low
cell content. A signiﬁcant proportion of patients in our series
underwent transplantation with CB units with cell contents
below the standard cell dose requirements. Furthermore, CB
TNC and CD34þ cell dose had no impact on achievement of
and time to CB engraftment. On the other hand, TNC content
showed inﬂuence on myeloid engraftment, only in a mi-
nority of the cases included in this analysisdthose achieving
engraftment beyond day 16. This group of patients may have
experienced an early CB graft dominance, which leads to a
relatively lower contribution of the TPD cells, as previously
described [23]. Also, HLA matching had no impact on long-
term CB engraftment. In our series, units with 4/6 match
had similar cellular content compared with those with 5/6
and 6/6 match. No signiﬁcant differences were found be-
tween patients showing engraftment before and beyond day
16, including CB unit cell content. However, other factors
may have contributed to an early CB graft dominance over
the TPD, such as CB unit T cell content [24]. Further studies
analyzing the number of infused T cells from a single CB unit
in this context could render practical information regarding
additional cell criteria for unit selection. TPD CD34þ dose
might have an impact on neutrophil recovery in all cases.
However, in our study, as TPD CD34þ cells infused were
homogenous among transplantations, with a median of
2.5  106 CD34þ cells/kg (IQR, 2.2 to 3), no correlation was
found.
Graft failure of both grafts was rare in our series (3 of 132
cases). Most of the cases showing CB graft failure or rejection
were related to poor post-thawing cell viability or presence
of donor-speciﬁc antibodies. Therefore, both factors should
be taken into account when selecting suitable units as pre-
viously suggested [7,25]. Among the 8 patients who showed
CB failure with engraftment of TPD cells, 5 maintained
acceptable blood counts until a salvage transplantation could
be performed.Single CB SCT has been associated with a potent graft-
versus-leukemia (GVL) effect and a low incidence of
serious GVHD [26]. The long follow-up of our study conﬁrms
the long-term efﬁcacy of the myeloablative haplo-cord
procedure for tumor control without increased risk of
GVHD. The low relapse rate of the series (20%), which in-
cludes a signiﬁcant proportion of high-risk patients with
active disease (37%), conﬁrms the potent GVL effect of the CB
graft using single units with relatively low cell content, with
lower rates of signiﬁcant GVHD compared with matched
unrelated donors and also double CB SCT [27]. Among factors
that could be involved in these results and need further
study are the dose and timing of antithymocyte globulin
[28], killer cell immunoglobulin-like receptor-ligand mis-
matching [29], and noninherited maternal antigens/inheri-
ted paternal antigens matching [30]. Although, previous
studies suggested better outcomes using CB units with
greater HLA-mismatch [9,26], the degree of HLA mismatch
was not an inﬂuencing factor in terms of EFS and OS in our
study. Also, the speed of engraftment of the CB unit did not
inﬂuence EFS.
In light of the observations of this study, as previously
reported [18], selection criteria of CB units in terms of TNC
and CD34þ content may be different when haplo-cord is
performed compared with single CB SCT. Because CB cell
dose had no impact on outcomes, haplo-cord SCT allows the
reduction of cell dose requirements, thereby expanding
donor availability. This could have a major economical
impact in the choice of donor in the setting of CB trans-
plantation, especially when double CB SCT is considered.
Also, certain patient populations, such as overweight pa-
tients and ethnic minorities [31], who otherwise would be
excluded for CB SCT, can beneﬁt from this procedure. Addi-
tionally, a less stringent cell dose requirement than that
needed for single CB SCT could allow the use of additional
selection criteria to improve transplantation outcomes, such
as matching for HLA-C [32], noninherited maternal antigens
[30], and natural killer cell alloreactivity [29], as previously
suggested [33].
The third-party cells infused in this procedure contribute
to the fast neutrophil recovery after transplantation [23].
However, the role of the third-party cells might exceed the
sole function of providing a bridge engraftment. Products of
leukapheresis collected from granulocyte colonyestimulat-
ing factoremobilized donors, although highly enriched in
CD34þ cells, contain other molecules with capacity of
enhancing the homing of CB- and BM-derived CD34þ cell in
mouse models [34].
M. Kwon et al. / Biol Blood Marrow Transplant 20 (2014) 2015e2022 2021In this study, most of the infection-related deaths
occurred after myeloid engraftment. Therefore, the delayed T
cell reconstitution remains an issue to be addressed also in
the haplo-cord setting [35,36]. However, 5 of the 6 CMV-
related deaths occurred in patients who underwent trans-
plantation before 2006, before ganciclovir was routinely
used as a preventative intervention.
In summary, our multicenter experience of myeloablative
haplo-cord SCT showed reliable and fast engraftment of
neutrophils and platelets, low incidence of early toxic mor-
tality, low incidences of acute and chronic GVHD, seemingly
good GVL effect, and favorable long-term outcomes for high-
risk patients. These results argue in considering the haplo-
cord SCT among the front-line options when allogeneic SCT
is needed. With this procedure, relatively low umbilical CB
cell dose had no impact on long term CB engraftment and
survival. Therefore, haplo-cord SCT expands donor avail-
ability reducing CB cell dose requirements.
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